Moderna (MRNA) stock plunged Thursday, Oct. 22, after Phase 3 trial results for its experimental cancer vaccine were leaked ahead of a major medical conference. Shares of Moderna fell 17. 6%, while Merck (MRK) dropped 1. 76%. The sell-off came despite positive trial results for intismeran autogene, Moderna’s personalized mRNA cancer vaccine developed with Merck. Moderna has been one of the S&P 500’s top-performing stocks this year, surging 587% year-to-date, mostly following its August announcement that the Phase 3 trial had succeeded. Merck shares have gained about 40% over the same period. Moderna stock surged 587% year-to-date.
POLARIS INSIGHTS